M

MAZZOTTA F.

Last name: MAZZOTTA F.

2018 (v1)

Publication

Metadata-only

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

Taramasso L. Tatarelli P. Ricci E.

Background: Dyslipidemia represents a significant non-infectious comorbidity among people living with HIV. The aim of this study is to evaluate the impact on lipid profile of switches from an efavirenz (EFV) or protease inhibitor/ritonavir (PI/r)-based regimen to a rilpivirine (RPV) or a once-daily integrase inhibitor-based regimen. Methods: We...

Uploaded on: April 14, 2023
2017 (v1)

Publication

Metadata-only

Weight gain: A possible side effect of all antiretrovirals

Taramasso L. Ricci E. Menzaghi B.

Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P = .0004), elvitegravir (P = .004), darunavir...

Uploaded on: April 14, 2023